Polyhydroxylated bile acids for treatment of biliary disorders
申请人:Qing Bile Therapeutics Inc.
公开号:US10543220B2
公开(公告)日:2020-01-28
The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α, 3α, 7α, 12α-tetrahydroxy-5β-cholanoic acid and 3α. 4α, 7α, 12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof.
POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS
申请人:British Columbia Cancer Agency Branch
公开号:EP2470553A1
公开(公告)日:2012-07-04
Polyhydroxylated Bile Acids for Treatment of Biliary Disorders
申请人:Wang Renxue
公开号:US20110263546A1
公开(公告)日:2011-10-27
The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow.
COMBINATION OF A POLYHYDROXYLATED BILE ACID AND A FARNESOID X RECEPTOR AGONIST
申请人:QING BILE THERAPEUTICS INC.
公开号:US20220227804A1
公开(公告)日:2022-07-21
The present invention relates to, in part, a combination therapy of a polyhydroxylated bile acid and a farnesoid X receptor agonist. The present invention also provides, in part, a pharmaceutical composition comprising a farnesoid X receptor agonist and a polyhydroxylated bile acid in the preparation of a medicament for treating a biliary disorder or a gastrointestinal disorder.